FORMULATION AND EVALUATION OF MUCOADHESIVE BUCCAL PATCHES OF ATOMOXETINE HYDROCHLORIDE

Atomoxetine hydrochloride (ATH) is a selective norepinephrinereuptake inhibitor commonly prescribed for the management of attention deficit hyperactivity disorder (ADHD). This study focuses on the development of mucoadhesive buccal patches for Atomoxetine Hydrochloride to enhance its bioavailability and provide extended drug release. The formulation process involves selecting appropriate polymers and excipients to optimize the mucoadhesive properties, mechanical strength, and drug release kinetics of the patches. Characterization studies will evaluate physical properties such as thickness, weight variation, and surface pH, along with mucoadhesive strength using techniques like texture analysis. In vitro drug release studies will be conducted to determine the release profile of Atomoxetine Hydrochloride, with data analysis using mathematical models to understand the underlying release mechanisms. The goal is to create an effective buccal delivery system that improves the therapeutic efficacy of Atomoxetine Hydrochloride.